{
  "docId": "019de517-75a1-7387-968b-d0dc513bf421",
  "docSlug": "e930bfcc8684afb6f5a4dd5442b5166d",
  "documentTitle": "Ocuphire Pharma | Investor Presentation Deck | 42 slides",
  "authorId": "ocuphire-pharma",
  "authorName": "Ocuphire Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 33,
  "pageCount": 42,
  "prevPage": 32,
  "nextPage": 34,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de517-75a1-7387-968b-d0dc513bf421/33",
  "deckHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421",
  "deckJsonHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421.json",
  "deckAnchorHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421#slide-33",
  "components": [
    {
      "bbox": {
        "h": 0.02,
        "w": 0.07,
        "x": 0.04,
        "y": 0.94
      },
      "kind": "image",
      "text": "Ocuphire",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c71236c5-ae5d-4291-bb0f-bee2211e9b4e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.446,
        "x": 0.475,
        "y": 0.402
      },
      "kind": "list",
      "text": "$130 million in regulatory and sales milestones",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11c73694-5fed-47fc-9f99-95c78fa32813",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.263,
        "x": 0.146,
        "y": 0.598
      },
      "kind": "list",
      "text": "Allows Ocuphire to focus on APX3330 development",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30a6e0ed-79a3-4554-adb1-e2da903a83ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.22,
        "x": 0.475,
        "y": 0.252
      },
      "kind": "list",
      "text": "$35 million upfront",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "495c7450-3b7d-4fbd-82a4-782ff65d3fd5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.446,
        "x": 0.475,
        "y": 0.672
      },
      "kind": "list",
      "text": "Tiered double digit royalties through 2040",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7981b81b-3a8d-4cab-9cd5-4676a4bf69d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.446,
        "x": 0.499,
        "y": 0.492
      },
      "kind": "list",
      "text": "First milestone payment of $10 million on FDA approval for pharmacologically-induced mydriasis indication",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0a72a80-f185-499e-bdad-1d4dd9fb4e79",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.446,
        "x": 0.475,
        "y": 0.302
      },
      "kind": "list",
      "text": "Fully funded development and commercialization for all 3 indications",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af833d57-6fa6-4dd0-9251-aae2092fd1f8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.263,
        "x": 0.146,
        "y": 0.252
      },
      "kind": "list",
      "text": "Partner for global commercialization",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4647619-702e-4db9-8dc2-ed97203ec3e4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.263,
        "x": 0.146,
        "y": 0.771
      },
      "kind": "list",
      "text": "Strengthens cash position into 2025",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d356cbac-8745-4006-8e6d-dc89b8202ff4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.263,
        "x": 0.146,
        "y": 0.425
      },
      "kind": "list",
      "text": "Fully funded development and commercialization costs for all 3 phentolamine indications",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3c640b8-069b-45f6-b5d3-ff1407e2fdd4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.013,
        "w": 0.018,
        "x": 0.953,
        "y": 0.953
      },
      "kind": "source-note",
      "text": "33",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d27f034-4359-4d7e-af3f-c2ed6a322b14",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.018,
        "w": 0.644,
        "x": 0.048,
        "y": 0.098
      },
      "kind": "title",
      "text": "Viatris Has Selected POS to be a Key Element of its Global Eye Care Division",
      "attrs": {},
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "77887db7-7c00-4db0-8cf4-ceb5b674ee03",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.899,
        "x": 0.048,
        "y": 0.06
      },
      "kind": "title",
      "text": "Global Partnership with Viatris for Phentolamine Ophthalmic Solution 0.75%",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8354c5f3-4207-4980-aa0a-68a41665a46c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "d21da411-b2a4-4b25-ac15-b957b0eff271",
      "evidence": "list/bullet: First milestone payment of $10 million on FDA approval for pharmacologically-induced mydriasis indication",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 42,
      "from": 29,
      "beatId": "691510f1-c63c-46db-bda1-6d94434f6f9b",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Slides 29-42 discuss key takeaways, corporate highlights, and future plans",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}